Since the first detection of a cluster of COVID-19 patients in China in late 2019, it becomes a global concern due to its transmissibility and ability to progress patients in severe respiratory failure and acute respiratory distress syndrome, which need intensive care unit support for a long time. We observed the repurposing use of remdesivir and favipiravir whether considered as a therapeutic option or not through survival rate and changes in biomarker during 10-day treatment stay in ICU.
The retrospective observational study in a tertiary care hospital dedicated to COVID-19 at Dhaka, Bangladesh was done at the peak of COVID-19 pandemic in Bangladesh. The mortality rate, length of ICU stays and eight prognostic biomarkers of patients treated with remdesivir and favipiravir was observed as one of the first ever reported experience in Bangladesh.
Among the critically ill patients in ICU, 26 (44.8%) died and 32 (55.2%) were cured during the study period and highest mean duration of stay in ICU was observed (14.33 days and 18.13 days) in FPV-treated patients. Mean of means for all biomarkers CRP (26.0) and d-Dimer (2.64) was recorded higher in favipiravir treated patients in death cases, but NLR, d-NLR, platelet, PLR was much higher in remdesivir treated patient of both death and improved cases. Though overall outcome variables between death and improved cases were not statistically significant (p<0.39)
The severity of disease progression in critically ill COVID-19 patients in ICU depends on comorbidities and hyper-responsive inflammatory or immunological biomarkers to predict. Though the emergency use authorization and repurposing use of different antivirals are still on trial, but remdesivir and favipiravir revealed not much hope in improving prognostic biomarkers, survival rate and disease progression at the peak of pandemic in Bangladesh.
Acinetobacter species are important opportunistic and nosocomial pathogens capable of causing both community and health careassociated infections (HAIs). The clinical specimens obtained from patients admitted in Holy Family Red Crescent Medical College and Hospital (HFRCMCH) from July 2013 to June 2015. All laboratory works were performed in department of microbiology and immunology of HFRCMCH. The infection rate was maximum in blood (67.7%) followed by urine (12.9%), tracheal aspirate (8.8%) and wound swab (3.32%). Most of the Acinetobacter were isolated from Intensive care unit (ICU) and Neonatal intensive care unit ( NICU). Acinetobacter displayed higher resistance to many antibiotics like Ampicillin which showed 96% resistance, Ceftriaxone 72%, Amikacin 72%, Imipenem 55%, Meropenem 60%, Tetraclycline 64%, Ciprofloxacin 60% and Cotrimoxazole showed 38% resistance. In conclusion, there was a high resistant rate to available and common antibiotics. It seems that infection control strategies may help to control the evolving problem of Acinetobacter infections and prevent an epidemic nosocomial life threatening infections.Bangladesh J Med Microbiol 2016; 10 (1): 18-21
Background: Since the first detection of a bunch of COVID-19 in late 2019, it become a global concern due to its transmissibility and ability to progress patients in severe respiratory failure and acute respiratory distress syndrome, which need intensive care unit support for a long time. We observed the repurposing use of remdesivir and favipiravir whether considered as a therapeutic option or not through survival rate and changes in biomarker during 10-day treatment stay in ICU.Materials and method: The retrospective observational study in a tertiary care hospital dedicated to COVID-19 at Dhaka, Bangladesh was done at the peak of COVID-19 pandemic in Bangladesh. The mortality rate, length of ICU stays and eight prognostic biomarkers of patients treated with remdesivir and favipiravir was observed as one of the first ever reported experience in Bangladesh.Results: Among the critically ill patients in ICU, 26 (44.8%) died and 32 (55.2%) were cured during the study period and highest mean duration of stay in ICU was observed (14.33 days and 18.13 days) in FPV-treated patients. Mean of means for all biomarkers CRP (26.0) and d-Dimer (2.64) was recorded higher in favipiravir treated patients in death cases, but NLR, d-NLR, platelet, PLR was much higher in remdesivir treated patient of both death and improved cases. Though overall outcome variables between death and improved cases were not statistically significant (p<0.39)Conclusion: The severity of disease progression in critically ill COVID-19 patients in ICU depends on comorbidities and hyper responsive inflammatory or immunological biomarkers to predict. Though the emergency use authorization and repurposing use of different antivirals are still on trial, but remdesivir and favipiravir revealed not much hope in improving prognostic biomarkers, survival rate and disease progression at the initial peak of pandemic in Bangladesh.
This study was carried out to determine the presence of resistance gene intl1 in E. coli isolated from surgical site wound infection in Holy Family Red Crescent Medical College Hospital. A total of 90 samples were collected from the different wound sites of patients admitted in surgical ward. The most predominant organism was E. coli 48(53.33%); followed by S. aureus 23(25.56%) and Pseudomonas 12(13.33%). Most of the isolated strains of E. coli were multidrug resistant. 46(96%) strains were shown resistant to ampicillin and most potent drug against E. coli was found to be imepenem. The extended spectrum Beta-lactamase (ESBL) producing E. coli were 21(43.75%).The resistance gene marker intl1 was detected in 32(67%) E. coli isolates.DOI: http://dx.doi.org/10.3329/bjmm.v4i2.10827
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.